



GP1644

PATENT

Attorney Docket No. HAR-001DV  
(6615/3)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Strominger et al.

SERIAL NO.: 08/991,628 GROUP NO.: 1644

FILING DATE: November 5, 1997 EXAMINER: T. Cunningham

TITLE: IDENTIFICATION OF SELF AND NON-SELF ANTIGENS IMPLICATED  
IN AUTOIMMUNE DISEASE

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8**

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231, on this 10th day of February, 2000.

February 10, 2000  
Date of Signature

Brenda T. Kowalcuk  
Brenda T. Kowalcuk

Assistant Commissioner for Patents  
Washington, D.C. 20231

FEB 17 2000

Sir:

TECH CENTER 1600/2900

Submitted herewith are:

Transmittal Form (1 pg.); Supplemental Information Disclosure Statement (2 pgs.); Supplemental PTO-1449 (1 pg.); Cited art C8; and a mailroom postcard and this Certificate of First Class Mailing.

FEB 15 2000

PATENT &amp; TRADEMARK OFFICE

# TRANSMITTAL FORM

Application Serial No.:	08/991,628
Filing Date:	November 5, 1997
First Named Inventor	Strominger et al.
Group Art Unit	1644
Examiner Name	T. Cunningham
Attorney Docket No.	HAR-001DV (6615/3)

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <ul style="list-style-type: none"> <li><input type="checkbox"/> Check Attached</li> <li><input type="checkbox"/> Copy of Fee Transmittal Form</li> </ul>	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <ul style="list-style-type: none"> <li><input type="checkbox"/> Formal Drawing(s)</li> </ul>	<input type="checkbox"/> Appeal Communication to Board of Patent Appeals and Interferences <ul style="list-style-type: none"> <li><input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition to Convert to a Provisional Application</li> <li><input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)</li> <li><input type="checkbox"/> Terminal Disclaimer</li> <li><input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application</li> <li><input type="checkbox"/> Small Entity Statement</li> <li><input type="checkbox"/> Request for Refund</li> <li><input type="checkbox"/> After Allowance Communication to Group</li> </ul>
<input type="checkbox"/> Amendment/Response <ul style="list-style-type: none"> <li><input type="checkbox"/> After Final</li> <li><input type="checkbox"/> Affidavits/declaration(s)</li> <li><input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets _____]</li> </ul>	<input type="checkbox"/> Status Letter <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Return Receipt Postcard</li> <li><input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8</li> <li><input type="checkbox"/> Additional Enclosure(s) (please identify below)</li> </ul>	
<input type="checkbox"/> Extension of Time Request		
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement		
<input checked="" type="checkbox"/> Supplemental Form PTO-1449		
<input checked="" type="checkbox"/> Copies of IDS Citations		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		

FEB 17 2000

TECH CENTER 1600/1600

## CORRESPONDENCE ADDRESS


## SIGNATURE BLOCK

Direct all correspondence to: Patent Administrator  
 Testa, Hurwitz & Thibeault, LLP  
 High Street Tower  
 125 High Street  
 Boston, MA 02110  
 Tel. No.: (617) 248-7000  
 Fax No.: (617) 248-7100

Date: February 10, 2000  
 Reg. No. 44,559  
 Tel. No.: (617) 248-7103  
 Fax No.: (617) 248-7100

Respectfully submitted,

Maureen A. Bresnahan  
 Maureen A. Bresnahan  
 Attorney for Applicants  
 Testa, Hurwitz & Thibeault, LLP  
 High Street Tower  
 125 High Street  
 Boston, MA 02110



PATENT  
Attorney Docket No. HAR-001DV  
(6615/3)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Strominger et al.  
SERIAL NO.: 08/991,628 GROUP NO.: 1644  
FILING DATE: November 5, 1997 EXAMINER: T. Cunningham  
TITLE: IDENTIFICATION OF SELF AND NON-SELF ANTIGENS IMPLICATED  
IN AUTOIMMUNE DISEASE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the references listed on the accompanying PTO Form 1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the references are enclosed.

**REMARKS**

In accordance with the provisions of 37 C.F.R. § 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **Filing Date** or before the mailing date of the **First Office Action** on the merits; or
- (2) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and
  - the requisite Statement is below, **OR**
  - the requisite fee under Rule 1.17(p), namely **\$240.00**, is included herein, or
- (3) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, **AND**
  - Applicant hereby Petitions the Commissioner to accept and consider the attached Information Disclosure Statement, **AND**
  - the requisite Statement is below, **AND**

Information Disclosure Statement

Serial No.: 08/991,628

Page 2 of 2



the requisite petition fee due under Rule 1.17(i)(I), namely \$130.00 is included herein.

It is respectfully requested that each of the references shown on the attached Form PTO-1449 be made of record in this application.

**STATEMENT**

As required under §1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]:

1. [E]ach item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application **not more than** three months prior to the filing date of the Information Disclosure Statement; or

2. [N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any** individual designated in §1.56(c) **more than** three months prior to the filing of the Information Disclosure Statement.

**FEE AUTHORIZATION**

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 20-0531. Any overpayments should be credited to said Deposit Account.


Respectfully submitted,

Date: February 10, 2000  
Reg. No. 44,559

Tel. No.: (617) 248-7103  
Fax No.: (617) 248-7100

BRESNAHA6615/3.941534-1

Maureen A. Bresnahan  
Maureen A. Bresnahan  
Attorney for Applicants  
Testa, Hurwitz, & Thibeault, LLP  
High Street Tower  
125 High Street  
Boston, Massachusetts 02110



FORM PTO - 1449  SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO.: HAR-001DV  APPLICANTS: Strominger et al.  SERIAL NO.: 08/991,628  FILING DATE: November 5, 1997  GROUP: 1644				
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Place of Publication, Relevant Pages, Date)								
2/25/00	C8	Hogenkamp et al., "Nucleotide Sequence of the Right 10% of Adenovirus Type 12 DNA Encoding the Entire Region E4", <i>Nucleic Acids Research</i> , Vol. 18, No. 10, April 1990, p. 3065.							
EXAMINER <i>Am. Dihm</i>	DATE CONSIDERED <i>2/25/00</i>								

BRESNAHA6615/3.941522-1